Production (Stage)
MediPharm Labs Corp.
LABS.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 89.93% | 39.81% | 36.96% | 11.98% | -17.31% |
| Total Depreciation and Amortization | -49.47% | -23.95% | -17.43% | 3.71% | 61.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -57.50% | -264.18% | 186.93% | 121.21% | 174.06% |
| Change in Net Operating Assets | -704.44% | -74.39% | -32.97% | 63.35% | -9.62% |
| Cash from Operations | -85.41% | -170.35% | 79.86% | 79.06% | 49.82% |
| Capital Expenditure | -87.82% | 64.11% | 87.51% | 18.04% | 15.68% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -107.52% | -100.99% | -101.98% | -103.64% | 2,204.86% |
| Total Debt Issued | -- | -- | -- | -29.80% | -- |
| Total Debt Repaid | 1.49% | 13.81% | -490.72% | 81.27% | 35.18% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -72.41% | -47.33% | -77.53% | -89.42% | 140.28% |
| Cash from Financing | -197.14% | 1.58% | -630.87% | -38.36% | 92.79% |
| Foreign Exchange rate Adjustments | 24.72% | 91.04% | -81.56% | -75.83% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -189.12% | -127.08% | -59.09% | 83.03% | 73.51% |